Skip to content
Screener

Alkermes ALKS Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.72B-30.8%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$667.5M-64.1%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$305.11M+1.4%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$175M-53.0%
LBR
LB Pharmaceuticals IncLBRX
$320.68M

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemJune 30, 2026December 31, 2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$511,529$388,570
Restricted cash731,206
Investments—short-term145,048199,645
Receivables, net456,477334,025
Inventory298,957196,625
Prepaid expenses and other current assets110,89579,090

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's cash & equivalents?
Alkermes (ALKS) reported cash & equivalents of $511.53M in Q2 2026.
How has Alkermes's cash & equivalents changed year-over-year?
Alkermes's cash & equivalents decreased by 1.9% year-over-year, from $521.2M to $511.53M.
What is the long-term trend for Alkermes's cash & equivalents?
Over 5 years (2020 to 2025), Alkermes's cash & equivalents has grown at a 7.3% compound annual growth rate (CAGR), from $272.96M to $388.57M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Alkermes's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude